Each point was worked out that day with the data available that day. Scale 0-10, same as the markers above: 5 is the index average and 10 means the score is capped at +3 standard deviations, not that it is perfect. The vertical axis zooms to fit this company, so two companies' charts are not directly comparable by eye; the darker line at 5 is in both.
Market and Valuation
Price & Market
Prev Close Price:$158.07
Open:$158.36
Day's Low:$150.26
Day's High:$159.79
Bid / Ask:-
Market Cap:61.50B
Enterprise Value:57.67B
52-Week Range
52-Week Low:$22.28
52-Week High:$176.66
Current position in 52-week range
52w Low-52w High
50-Day Avg:$96.62
200-Day Avg:$59.60
Volume
Volume Today:20,223,717
Avg Volume (3m):16,140,367
Avg Volume (10d):11,788,360
52-Week Change:+526.27%
vs S&P 500, 52 weeks:-
Beta:1.11
Valuation Multiples
PER Trailing:-
PER Forward:-34.47
PEG Ratio:-
Price / Book:9.09
Price / Sales (TTM):27.60
EV / Revenue:25.89
EV / EBITDA:-26.27
Dividends
Current yield:-
Annual Dividend Rate:-
Dividend Trailing:$0.00
Yield Trailing:0.00%
5-Year Avg Yield:-
Payout Ratio:0.00%
Last Ex-Dividend Date:-
Valuation Context
P/E vs sector (indicative)
Most Recent Quarter:-
Fiscal Year (Next):-
Loading historical OHLCV database...
Date
Open
High
Low
Close
Volume
Financial Statements TTM (Trailing 12 Months)
Income Statement
Total Revenue (TTM):2.23B
Gross Profit:−1.47B
EBITDA:−2.20B
Net Income (TTM):−3.15B
Rev Growth (YoY):+2.10%
Earnings Growth (YoY):-
Quarterly earnings growth (YoY):-
Margins
Gross Margin:-
EBITDA Margin:-
Operating Margin:-
Net Margin:-
Per Share
EPS Trailing (TTM):-
EPS Forward (Est.):$-4.47
Revenue Per Share:$5.66
Cash Per Share:-
Book Value:$16.95
Last Dividend:-
Ex-Dividend Date:-
Last Split:-
Balance Sheet & Liquidity
Total cash:5.14B
Total Debt:1.29B
Net Debt (Debt - Cash):−3.85B (net cash)
Debt / Equity:19.04%
Current Ratio:2.30
Quick Ratio:2.07
Cash Flows
Operating Cash Flow:−1.07B
Free Cash Flow (FCF):299.25M
FCF Yield (FCF / Market Cap):-
Enterprise Value:57.67B
EV / Revenue:25.89
EV / EBITDA:-26.27
Profitability
ROE (Return on Equity):-39.00%
ROA (Return on Assets):-13.26%
PER Trailing:-
PER Forward:-34.47
Price / Book:9.09
PEG Ratio:-
52-Week Change:+526.27%
S&P 500 change, 52 weeks:+14.80%
Historical Evolution (Last 4 Years)
Income Statement
Balance Sheet
Cash Flow
EPS and Earnings Per Share
Key EPS Metrics
EPS Trailing (TTM):$-7.78
EPS Forward (Est.):$-4.47
PER Forward:-
PEG Ratio:-
Growth and Margins
Earnings Growth YoY:-
Quarterly Earnings Growth YoY:-
Rev Growth YoY:-
Net Margin:-
Gross Margin:-
EBITDA Margin:-
Per Share
Revenue Per Share:$5.66
Cash Per Share:-
Book Value:$16.95
Cash Flows (TTM)
Free Cash Flow:299.25M
Operating Cash Flow:−1.07B
EBITDA:−2.20B
Total Revenue (TTM):2.23B
Net Income (TTM):−3.15B
Fiscal Year (Last):-
EPS Surprise History - Last 4 Quarters
Actual vs. Analyst Estimates · Green = beat expectations · Red = missed
Quarter
Period
Actual EPS
Estimated EPS
Difference
Surprise %
Currency
Ownership Structure
Ownership Distribution
% Insiders:-
% Institutional:-
% Inst. (of Float):-
No. of Institutions:-
Visual distribution
InsidersInstitutionalFree Float
Shares & Short Interest
Shares Outstanding:399,235,889
Float (free shares):372,259,520
Short interest (shares):39,151,532
Short % of float:-
Short Ratio (days to cover):1.36
Short interest, prior month:-
Short Interest Date:-
Governance Score (1=Best, 10=Worst)
Overall risk:-
Audit Risk:-
Board risk:-
Compensation Risk:-
Shareholder rights risk:-
Top Institutional Holders
Position Change: ▲ Increased · ▼ Reduced · = Unchanged
Organization
Report Date
% Shares
No. Shares
Value (USD)
Change %
Top Mutual Funds
Position Change: ▲ Increased ▼ Decreased = Unchanged
Fund
Report Date
% Shares
No. Shares
Value (USD)
Change %
Recent Insider Trades
Executive / Insider
Title
Date
Action
Shares
Options Chain
CALLS
Strike
Last
Bid
Ask
Vol.
O.I.
IV
PUTS
Strike
Last
Bid
Ask
Vol.
O.I.
IV
Sentiment Metrics
Put/Call Ratio (Volume):-
Put/Call Ratio (O.I.):-
Max Pain (estimated):-
Total O.I. Calls:-
Total O.I. Puts:-
Expected move
Average IV (Calls ATM):-
Average IV (Puts ATM):-
Days to Expiration:-
Expected move (±):-
Moderna, Inc. (MRNA) SEC filings: 10-K, 10-Q and 8-K
Direct links to financial reports filed with the SEC.
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Few finance sites let you get this far, and none we know of also shows you where its knowledge ends. If this way of working convinces you, the thing almost nobody catches in time can reach you by email: the big insider buys — executives and major shareholders putting in their own money — the same day they report them to the SEC, with the Form 4 linked. It takes three steps and none of them costs anything: create the account, confirm the email we send you, then switch the alert on in your profile (the icon at the top right). It starts off and it goes off again with the same click. Along the way all three are saved: your simulator portfolios, your personal portfolio and your Academy progress, synced across devices.
No card. No spam.
Moderna, Inc. (MRNA): Quantitative Analysis
Moderna, Inc. (MRNA) — Healthcare — Biotechnology. MRNA is in the S&P 500 today. Model factor scores and market data, recalculated every trading day.
So far in 2026, MRNA has returned +422.3% against +12.2% for the S&P 500 (SPY): total return, dividends included on both sides, from Dec 31, 2025 to Sep 18, 2026.
Its strongest factor is momentum (Z 2.25, ranked 8 of 497); its weakest is quality (Z -1.70, ranked 473 of 473). Each factor ranks only the companies with data for it, and the multifactor score only those with all four: that is why the totals differ.
Factor scores
The Z-Score is how many standard deviations the company sits from the index average: 0 is average, positive is better than average, negative is worse.
We save the portfolios you design, your own portfolio and your Academy progress, synced across devices.
Free, no card. Two automatic emails and no more: the one that confirms your address and the welcome one when you confirm it. After that nothing reaches you unless you switch it on yourself. And the thing almost nobody catches in time: the big insider buys — executives and major shareholders putting in their own money, the same day they report them to the SEC. One click in your profile turns it on; one click turns it off.